Synthetic Peptide Impurity Analysis on Waters Reversed-Phase Columns

Importance of the Topic

Peptide-based drugs are gaining traction as biotherapeutics due to their potency, specificity, and ease of synthetic modification. Ensuring the purity of synthetic peptides is critical because impurities arising during solid phase peptide synthesis or storage can compromise safety and efficacy. Reliable impurity profiling supports quality control and regulatory compliance in peptide manufacturing.

Objectives and Study Overview

This study aimed to establish a rational approach for selecting reversed-phase columns to separate synthetic peptide impurities under generic gradient conditions. Seven representative peptides were screened on four Waters® Peptide Separation Columns and three additional reversed-phase chemistries. The goal was to compare selectivity, retention behavior, and peak capacity to guide method development.

Methodology and Instrumentation

Synthetic peptides (bivalirudin, ceruletide, desmopressin, lanreotide, secretin, salmon calcitonin, PTH 1–34) were reconstituted at 2 mg/mL in water, then diluted in 0.1 % formic acid. Chromatography used an ACQUITY UPLC H-Class Bio System at 60 °C and 0.3 mL/min, injecting 2.5–10 µL. Mobile phases alternated between 0.1 % TFA, 0.1 % FA, and 20 mM ammonium formate pH 10 in water and acetonitrile under a consistent gradient slope. Detection was by ACQUITY UPLC TUV at 214 nm; data were managed with MassLynx v4.1.

Instrumentation

• ACQUITY UPLC H-Class Bio System
• ACQUITY UPLC Peptide BEH C18 130 Å and 300 Å; Peptide CSH C18 130 Å; Peptide HSS T3 100 Å; CSH Phenyl-Hexyl 130 Å; CSH Fluoro-Phenyl 130 Å; BEH C8 130 Å columns
• ACQUITY UPLC TUV Detector (214 nm, 5 mm titanium cell)
• MassLynx™ Software v4.1

Main Results and Discussion

Column screening revealed distinct selectivity and retention patterns across peptide chemistries and mobile phases. Key findings:

• Bivalirudin impurities (deamidation, water loss, glycine insertion, fragments, diastereomers) were differentially resolved by each column and mobile phase, highlighting the impact of ion pairing and pH.
• Ceruletide displayed unusually high retention on positively charged CSH phases under acidic conditions due to sulfonic acid–stationary phase interactions, which reversed at pH 10.
• Desmopressin degradation products (amino acid insertions, deamidation during storage) required high loading capacity and sharp peak profiles, favoring CSH columns for impurity detection.
• Lanreotide exhibited multiple isomeric forms; formic acid mobile phases provided superior resolution of these isomers compared to TFA.
• Secretin’s aspartimide isomers were separated unevenly across phases; shallow gradients and phase selection were critical to resolve five isomers under TFA.
• Salmon calcitonin impurities (sulfur insertion, acetylation, water gain/loss) and PTH (1–34) oxidation and truncation fragments demonstrated that column choice must match peptide hydrophobicity and impurity profile.

Overall, Peptide BEH C18 phases offer general-purpose retention (300 Å for large peptides, 130 Å for small). Peptide CSH C18 delivers narrow peaks and high loadability. Peptide HSS T3 provides strong retention for short hydrophilic peptides. CSH Phenyl-Hexyl and Fluoro-Phenyl impart unique selectivity and lower retention, while BEH C8 may excel for very hydrophobic sequences.

Benefits and Practical Applications

Screening a focused set of columns accelerates method development by identifying optimal conditions for impurity profiling in early-stage synthesis and final release testing. The approach ensures comprehensive coverage of known and unknown impurities, supports high-throughput workflows, and strengthens analytical confidence for QA/QC labs.

Future Trends and Opportunities

Emerging stationary phases (e.g., CORTECS C18+, CORTECS T3) and ultra-high-throughput UHPLC systems promise faster, higher-resolution impurity screening. Integration with automated column selection software and advanced MS detection will enhance the speed and sensitivity of peptide analytics. Continued innovation in hybrid chemistries and data-driven method optimization will expand capabilities in peptide drug development.

Conclusion

No single reversed-phase column suits all synthetic peptide impurity analyses. A targeted screening strategy across complementary chemistries, combined with pH and ion-pairing adjustments, yields robust separations. Guided selection based on peptide properties ensures reproducible, high-resolution impurity profiling.

References

• Ali R et al. New peptide based therapeutics approaches. Omics Group eBooks, 2014.
• Vliehe P et al. Synthetic therapeutic peptides: science and market. Drug Disc Today 2010;15(1/2).
• Merrifield RB. Solid phase peptide synthesis. J Am Chem Soc 1963;85:2149–2154.
• Eggen I et al. Control strategies for synthetic therapeutic peptide APIs Part III: Manufacturing process considerations. Pharm Technol 2014;38(5).
• Bracke N et al. Related impurities in peptide medicines. J Pharm Biomed Anal 2014;101:2–30.
• Koza S, Chambers EE. Selecting a reversed-phase column for peptide mapping of a biotherapeutic. Waters App Note 720005924EN, 2017.
• Wikipedia. Bivalirudin. 2018.
• Mayo Clin. Bivalirudin description.
• DrugBank. Ceruletide DB00403.
• Wikipedia. Desmopressin.
• Wikipedia. Lanreotide.
• DrugBank. Secretin DB00021.
• Toney K et al. Aspartimide formation in porcine POMC. J Biol Chem 1993;268(2):1024–1031.
• RxList. Miacalcin side effects.
• GenScript. PTH (1–34) human peptide RP01001.